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Abstract
Background: Colon adenocarcinomas are refractory to a number of widely used anticancer
agents. Multifactorial mechanisms have been implicated in this intrinsically resistant phenotype,
including deregulation of cell death pathways. In this regard, the p53 protein has a well established
role in the control of tumor cell response to DNA damaging agents; however, the relationship
between p53-driven genes and drug sensitivity remains controversial. The present study
investigates the role of the p53/p21 system in the response of human colon carcinoma cells to
treatment with the cytotoxic agent doxorubicin (DOX) and the possibility to modify the
therapeutic index of DOX by modulation of p53 and/or p21 protein levels.
Methods: The relationship between p53 and p21 protein levels and the cytotoxic effect of DOX
was investigated, by MTT assay and western blot analysis, in HCT116 (p53-positive) and HT29
(p53-negative) colon cancer cells. We then assessed the effects of DOX in two isogenic cell lines
derived from HCT116 by abrogating the expression and/or function of p53 and p21 (HCT116-E6
and HCT116 p21-/-, respectively). Finally, we evaluated the effect of pre-treatment with the
piperidine nitroxide Tempol (TPL), an agent that was reported to induce p21 expression
irrespective of p53 status, on the cytotoxicity of DOX in the four cell lines. Comparisons of IC50
values and apoptotic cell percentages were performed by ANOVA and Bonferroni's test for
independent samples. C.I. calculations were performed by the combination Index method.
Results: Our results indicate that, in the colon carcinoma cell lines tested, sensitivity to DOX is
associated with p21 upregulation upon drug exposure, and DOX cytotoxicity is potentiated by pre-
treatment with TPL, but only in those cell lines in which p21 can be upregulated.
Conclusions: p21 induction may significantly contribute to the response of colon
adenocarcinomas cells to DOX treatment; and small molecules that can exploit p53-independent
pathways for p21 induction, such as TPL, may find a place in chemotherapeutic protocols for the
clinical management of colorectal cancer, where p53 function is often lost, due to genetic or
epigenetic defects or to post-transcriptional inactivating mechanisms.
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Colorectal cancer is the second most common cause of
cancer-related mortality in Western countries, with about
1 million new cases every year diagnosed world-wide and
500,000 patients dying from the disease [1]. Of the
patients, 30% have advanced disease at presentation,
either locally or at distant sites; in this setting, chemother-
apy remains the only viable therapeutic option. However,
even this option is severely hindered by the inherent
resistance of metastatic colon cancer to many currently
used anticancer agents. A variety of mechanisms by which
cancer cells resist chemotherapy have been described,
including enhanced export of drugs from cancer cells and
alterations in drug metabolism and/or in drug-target
interactions [2]. In addition, the response of cancer cells
to genotoxic therapies may be critically impaired by
defects in the response mechanisms to DNA damage [3]
or in cell cycle regulatory pathways [4].
Over the past decade, induction of apoptosis has emerged
as a major event in tumor cell response to cytotoxic agents
(for a recent review see [5]). This view, although recently
challenged by some Authors [6], has attracted considera-
ble attention on deregulation of cell death pathways as a
key determinant of drug resistance.
Two separable, although extensively cross-talking, path-
ways leading to apoptosis have been characterized [7,8].
The extrinsic pathway is initiated by ligation of transmem-
brane receptors to activate membrane proximal "activa-
tor" caspases, which in turn cleave and activate
downstream "effector" caspases. The intrinsic pathway
requires disruption of the mitochondrial membrane and
the release of mitochondrial proteins, two events that are
regulated by the opposing actions of pro- and antiapop-
totic Bcl-2 family members. "Intrinsic stresses", such as
those produced by DNA-damaging agents, activate the
intrinsic apoptotic pathway; the multifunctional tran-
scription factor p53 is thought to be part of a "fast track"
connection between nuclear DNA damage and the intrin-
sic pathway machinery [9]. p53 regulates multiple
responses to genotoxic stress by transcriptional activation
or repression of a number of genes encoding proteins
involved in cell cycle control (p21WAF1/Cip1), DNA repair
(gadd45), and apoptosis (e.g. Bax, Bcl2 and survivin)
[10]. Mutations in p53 and in the p53 pathway can pro-
duce multidrug resistance in vitro and in vivo, and reintro-
duction of wildtype p53 into p53 null tumor cells can re-
establish chemosensitivity [11]. p53 status is not a univer-
sal predictor of treatment response, in part because not all
drugs absolutely require p53 for their apoptotic function
[12] and in some settings, p53 loss can enhance drug-
induced apoptotic cell death [13]. Still, loss of p53 func-
tion correlates with multidrug resistance in many tumor
types [11] and the observation that this is a common
defect in human tumors has spurred an active search for
strategies aimed at directly activating cell death pathways
downstream of p53. In this scenario, the role played by
the cyclin-dependent kinase inhibitor p21 is particularly
intriguing, as this protein can be activated by both p53-
dependent and p53-independent mechanisms and can
assume pro- or anti-apoptotic functions, depending on
the cellular context (for a review see [14]).
The present research focuses on the role of p21 in tumor
cell response to treatment with cytotoxic agents, and on
the possibility to improve the therapeutic index of such
agents by modulating p21 status by p53-dependent and
independent pathways. The following issues have been
addressed: (a) analysis of the relationship between p21
status and sensitivity to treatment with the cytotoxic anti-
cancer agent doxorubicin (DOX) in p53-positive and -
negative colon cancer cell lines; (b) design of treatment
strategies based on the use of small molecules able to
modulate p21 status; for the present study we have used a
low molecular weight, stable nitroxide radical, 4-hydroxy-
2,2,6,6,tetramethylpiperidne-N-oxyl (also known as Tem-
pol, TPL; figure 1) that was shown to exert an antiprolifer-
ative effect against different cancer cell lines [15] and to
increase p21 levels in a p53-null human leukemic cell line
[16]. Our data indicate that p21 modulation may
Structure of 4-hydroxy-2,2,6,6,tetramethylpiperidne-N-oxyl (also known as Tempol, TPL)Figure 1
Structure of 4-hydroxy-2,2,6,6,tetramethylpiperidne-N-oxyl 
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colon cancer cell lines tested.
Methods
Reagents
Standard chemicals, including 4-hydroxy-2,2,6,6-tetrame-
thylipiperidine-N-oxyl (Tempol, TPL) and cell culture rea-
gents were purchased from Sigma-Aldrich srl. (Milan,
Italy), unless otherwise indicated; doxorubicin (DOX)
was kindly provided by Dr. A Suarato (Pfizer-Pharmacia,
Milan, Italy).
Cell lines
The human colon carcinoma cell lines HCT116, HT29
(obtained from ATCC, Rockville, MD) and HCT116 p21-
negative cells (HCT116 p21-/-), kindly provided by Dr B.
Vogelstein (Johns Hopkins University, Baltimore, MD,
USA), were maintained in DMEM medium supplemented
with 10% FBS (Mascia Brunelli); the HCT116-E6 cell line,
obtained from HCT116 cells by transfection with pCMV-
neo-E6 plasmid (provided by Dr B. Vogelstein) contain-
ing the HPV16-E6 human gene, was maintained in
ISCOVE medium supplemented with 10% FBS and
geneticin (500 µg/ml). All the cell lines were cultured at
37°C, in an atmosphere of 5% CO2 and 95% humidity.
Cytotoxicity assays
The effects of DOX and/or TPL on cell growth were
assessed by the MTT assay [17]. Briefly, cells were seeded
onto 96-well plates and allowed to grow for 24 h prior to
treatment. Three different treatment schedules were used:
a) 24 h medium, 1 h DOX (0.05 – 10 µM) followed by 72
h incubation in drug-free medium; b) 24 h TPL (0.05 – 10
mM) followed by 72 h incubation in drug-free medium;
c) 24 h TPL followed by 1 h DOX and by 72 h incubation
in drug-free medium. For combination experiments, the
whole range of DOX concentrations (0.05 – 10 µM) was
tested following pretreatment with fixed TPL concentra-
tions, corresponding to the IC25 or IC50values obtained for
each cell line according to schedule (b). At the end of the
treatment period, 50 µl of MTT (2 mg/ml in PBS) were
added to each well at 37°C for 3 h and the reduction of
MTT by viable cells was measured colorimetrically at 570
nm, using a Universal Microplate Reader EL800 (Bio-Tek
Instruments). IC25 and IC50 values (i.e. the concentrations
yielding 75% and 50% cell survival fractions, respectively)
were calculated according to the median effect equation
and analysis of the interaction between DOX and TPL was
performed as described by Chou & Talalay [18].
Transfection of HCT116 cells
Transfection of HCT116 cells with the pCMVneo-E6 plas-
mid was performed by electroporation as described by
Yanez and Porter [19], using a Bio-Rad Gene Pulser unit at
the following conditions: 280 V, 960 µF. 48 h post-trans-
fection the cells were selected by adding 500 µg/ml of
geneticin to the culture medium. The efficiency and stabil-
ity of transfection were checked by Western blot analysis
of whole cell lysates. Control cells were mock-transfected
with the pCMVneo plasmid.
Preparation of cell extracts and immunoblotting
The expression of p53 and p21, before and after 1 h expo-
sure to DOX (1.0 and 10 µM) followed by 23 h incubation
in drug-free medium, or after 24 h exposure to TPL (1.0
and 2.5 mM), was evaluated by Western blot analysis of
total protein extracts (lysis buffer: NP40 1%, leupeptin 10
µg/ml and aprotinin 10 µg/ml in TBS). Protein concentra-
tion in the cellular lysates was determined by the BCA
assay (Pierce, Rockford, IL, USA). 15 µg of protein extract/
lane were loaded onto 11% polyacrylamide gels and sep-
arated under denaturing conditions. Protein samples were
then transferred onto nitrocellulose membrane and West-
ern blot analysis was performed by standard techniques.
using a mouse anti-p53 monoclonal antibody (DO-1;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and
a rabbit anti-p21 polyclonal antibody (C-19; Santa Cruz
Biotechnology). Proteins were visualized using peroxi-
dase-conjugated anti-mouse and anti-rabbit secondary
antibodies (Amersham Pharmacia Biotech) and the ECL
Plus Western Blotting Detection Reagents (Amersham
Pharmacia Biotech).
Densitometric analysis was performed using the Scion
Image software (Scion Corporation, Frederick, MD).
Flow cytometric analysis of apoptotic cells
The presence of apoptotic cells in HCT116, HT29,
HCT116-E6 and HCT116 p21 -/-, before and after 1 h
exposure to DOX (1.0 and 10 µM) followed by 23 h incu-
bation in drug-free medium, was evaluated by flow cyto-
metric analysis, using a Becton Dickinson FACScalibur
flow cytometer. Cells were detached by trypsinization,
washed in phosphate-buffered saline (PBS) and fixed in
ice-cold 70% ethanol for 20 min at -20°C. After an addi-
tional wash in PBS, DNA was stained with 50 mg/ml pro-
pidium iodide in PBS in the presence of RNAse A (30 U/
ml) at 37°C for 30 minutes. 5 × 105 cell samples were ana-
lyzed and data were processed using the CellQuest soft-
ware (Becton Dickinson). The percentage of apoptotic
cells in each sample was determined based on the sub-G1
peaks detected in monoparametric histograms.
Statistical analysis
Comparisons of IC50 values and apoptotic cell percentages
in the four different cell lines were performed by ANOVA
and Bonferroni's test for independent samples. C.I. calcu-
lations an relative statistical analysis were performed as
described by Chou and Talalay [18]. According to this
method, a combination index (C.I.) can be calculated fromPage 3 of 10
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DOX and/or TPL as single agents and in combination. C.I.
values approximating 1.0 indicate additive interactions
between the two agents; C.I. < 1.0 indicate synergy and,
conversely, C.I. > 1.0 indicate antagonism.
Results
Cytotoxicity assays
Figure 2 shows the dose-response curves for HCT116,
HT29, HCT116-E6 and HCT116 p21-/- cells following 24
h incubation in drug-free medium, 1 h exposure to DOX
and 72 h incubation in drug-free medium. IC50 values cal-
culated from these data are reported in table 1; the resist-
ance index (R.I.) is calculated as the ratio between the IC50
value obtained for each cell line and that obtained for
HCT116 cells. The HT29 cell line, which carries a mutant
form of the p53 gene, is significantly more resistant to the
cytotoxic action of DOX than the HCT116 cell line, carry-
ing a wild-type p53 gene (IC50 values: 2.197 ± 0.11 µM vs.
0.38 ± 0.03 µM, respectively; mean ± s.e.m. of 4–6 exper-
iments, p < 0.05). HCT116-E6 cells are 2-fold more resist-
ant to DOX than HCT116 cells (IC50: 0.770 ± 0.06 µM;
mean ± s.e.m. of 4–6 experiments, p < 0.05 vs. HCT116),
while HCT116 p21-/- cells are 14-fold more resistant to
DOX than HCT116 cell line (IC50: 5.457 ± 0.163 µM;
mean ± s.e.m. of 4–6 experiments, p < 0.05 vs. HCT116),
in spite of the presence of a wild type form of p53.
Immune detection of p53 and p21
Figure 3 shows the expression of p53 (A) and p21 (C) pro-
teins, before and after exposure to DOX (1 and 10 M for
1 h followed by 23 h in drug-free medium), in the four
cell lines tested; panels B and D report the densitometric
analysis of p53 and p21 immune reactive bands,
respectively. In the absence of drug treatment, it is possi-
ble to observe that HT29 cells show higher p53 but lower
p21 protein levels, as compared with the HCT116 cell
line. DOX treatment induces a dose-dependent increase in
both p53 and p21 levels in HCT116 cells, whereas in
HT29 cells p53 protein levels are not significantly modi-
fied by the treatment and p21 protein levels are only
detectable when 25 µg of protein extract/lane are loaded
onto the gel (instead of the 15 µg loaded for the other cell
lines), and even then only at the highest DOX concentra-
tion used. As expected, HCT116 E6 cells do not show
detectable p53 levels, both under baseline conditions and
following DOX treatment; in contrast in HCT116-E6 cells
p21 levels are increased by DOX treatment in a dose-
dependent fashion, although to a lesser extent than in
HCT116 cells. HCT116 p21-/- cells show higher baseline
expression levels of p53 compared with HCT116 cells and
DOX treatment in this cell line enhances p53 expression
to a an even greater extent than in HCT116 cells line. As
expected, p21 is undetectable in HCT116 p21-/- cells, and
DOX treatment does not modify the intracellular levels of
this protein.
Evaluation of apoptotic cells by flow cytometric analysis
Figure 4 shows the percentage of apoptotic cells following
treatment of the four colon cell lines with DOX (1.0 and
10 µM) for 1 h followed by 23 h in drug-free medium. No
significant differences in the percentage of apoptotic cells
were observed in untreated HCT116, HT29, HCT116-E6
and HCT116 p21-/- cells. Exposure to DOX induces con-
centration-dependent increases in apoptotic cells in all
the cell lines tested; HCT116-E6 cells were the least sus-
ceptible apoptosis induction by DOX.
Dose-response curves of HCT116 (■), HT29 (▲), HCT116E6 (▼), and HCT116 p21-/- (●) cells after 1 hour exposure t  DOX followed by 72 h incubation in drug free medium (mean ± s.e.m. of 4–6 experiments)Figure 2
Dose-response curves of HCT116 (■), HT29 (▲), 
HCT116E6 (▼), and HCT116 p21-/- (●) cells after 1 hour 
exposure to DOX followed by 72 h incubation in drug free 
medium (mean ± s.e.m. of 4–6 experiments).
?
µ
Table 1: IC50values obtained after 1 h exposure to DOX followed 
by 72 h incubation in drug free medium (mean ± s.e.m. of 4–6 
independent experiments).
cell lines IC50 (µM) R.I.a
HCT116 0.38 ± 0.03 1.0
HT29 2.37 ± 0.13 * 6.24
HCT116 E6 0.732 ± 0.06 * 1.93
HCT116 p21-/- 4.98 ± 0.32 * 13.10
*p < 0.05 vs HCT116
aThe resistance index (R.I.) was calculated as the ratio between the 
IC50 values obtained for each cell line and that of HCT116 cellsPage 4 of 10
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p53 (A) and p21 (C) protein levels in HCT116, HT29, HCT116 E6 and HCT116 p21-/- cells following 1 h exposure to DOX 
and 23 h incubation in drug-free medium. Panels B and D: densitometric analysis of p53 and p21-immune reactive bands, 
respectively (white bars: untreated; light grey bars: DOX 1 µM; dark grey bars: DOX 10 µM).Page 5 of 10
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Table 2 reports the IC25 and IC50 values obtained for the
four cell lines after 24 h of continuous TPL exposure fol-
lowed by 72 h in drug-free medium. TPL can be observed
to inhibit cell growth in all four cell lines; although no sig-
nificant differences can be detected among IC50 values,
HCT116 p21-/- cells appear to be less responsive than the
other three cell lines. Figure 5 shows that 24 h exposure to
TPL (1 and 2.5 mM) induces a dose-dependent increase in
both p53 and in p21 levels in HCT116 cells, whereas in
HT29 cell line TPL treatment only induces a dose-depend-
ent increase in p21 expression. Exposure of HCT116-E6
cells to TPL (1 and 2.5 mM) for 24 h does not induce any
variations in p53 expression, while a dose-dependent
increase in p21 expression can be observed following
treatment with the nitroxide. In HCT116 p21-/- cells TPL
induce a slight increase in p53 protein levels but, as
expected, p21 levels were unaffected by TPL treatment.
Effects of TPL pretreatment on DOX-induced cytotoxicity
Figure 6 shows the effect of 24 h pretreatment with TPL, at
fixed concentrations corresponding to the IC25 and IC50
values obtained for each cell line, on DOX cytotoxicity.
The cells' response to DOX is expressed as the IC50 values
derived from dose/response curves obtained after 1 h
exposure to DOX with or without pretreatment with TPL
(24 h), followed by 72 h in drug-free medium. Analysis of
cytotoxicity data shows a synergistic interaction (C.I.<1)
between DOX and TPL for both TPL concentrations in
HCT116 cells and in HCT116-E6 and HT29 cells at the
lower concentration; only additive effects (C.I. ≈ 1) can be
observed in HCT116 p21 -/- cells. IC50 values for DOX and
Percentage of apoptotic cells in HCT116, HT29, HCT116 E6 and HCT116 p21-/- cells before and after 1 h exposure to DOX followed by 23 h incubation in drug-free medium (white bars: untreated; light grey bars: DOX 1 µM; dark grey bars: DOX 10 µM)Figur  4
Percentage of apoptotic cells in HCT116, HT29, HCT116 E6 and HCT116 p21-/- cells before and after 1 h exposure to DOX 
followed by 23 h incubation in drug-free medium (white bars: untreated; light grey bars: DOX 1 µM; dark grey bars: DOX 10 
µM). Mean ± s.e.m. of 3 independent experiments.
Table 2: IC50values obtained after 24 h exposure to TPL followed by 72 h incubation in drug free medium. (mean ± s.e.m. of 4–6 
independent experiments).
Cell lines IC25 (µM) IC50 (µM) R.I.a
HCT116 280.00 ± 39.21 560.00 ± 77.78 1.0
HT29 320.40 ± 50.03 665.63 ± 102.91 1.19
HCT116 E6 400.06 ± 60.00 837.3 ± 103.99 1.49
HCT116 p21-/- 700.00 ± 99.14 1114.55 ± 182.2 1.99
a The resistance index (R.I.) was calculated as the ratio between the IC50 values obtained for each cell line and that of HCT116 cellsPage 6 of 10
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p53 (A) and p21 (C) protein levels in HCT116, HT29, HCT116 E6 and HCT116 p21-/- cells following 24 h exposure to TPL. 
Panels B and D: densitometric analysis of p53 and p21-immune reactive bands, respectively (white bars: untreated; light grey 
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in table 3.
Discussion
Resistance of colorectal cancer to established treatment
regimens remains a major concern in oncology; thus
attempts at improving the survival of patients affected by
this disease depend largely on strategies targeting tumor
cell resistance, which cannot be rationally planned with-
out a detailed knowledge of the mechanisms underlying
this phenomenon. A current paradigm regarding cancer
chemotherapy indicates disabling of the intrinsic apop-
totic pathway as a key factor in the response of tumor cells
to anticancer drugs [3,5,12]. Therefore, strategies aiming
at re-establishing the cell's capability to activate a cell
death program are an area of active research. The present
study was performed in order to define the role of the
p53/p21 pathway in the response of colorectal carcinoma
cells to DOX, a cytotoxic agent that is typically devoid of
effects in this tumor type. The results obtained in our cyto-
toxicity studies indicate that in the cell lines examined p53
status is not unequivocally related to the response to
DOX: in fact, while p53-deficient cells (HT-29, HCT116-
E6) are indeed less responsive than the p53/wt parental
HCT116 cell line, the highest resistance index was
obtained for HCT116 p21-/- cells, harboring two wildtype
p53 alleles. As expected, treatment with DOX leads to p53
upregulation in the cell lines expressing wildtype p53; this
effect has been thoroughly documented in colon cancer
cells as well as in tumor cell lines derived from other tis-
sues, and has been attributed to phosphorylation and sub-
sequent stabilization of p53, possibly through activation
of DNA-dependent protein kinase or ATM (ataxia-
teleangectasia mutated) kinase (see e.g. [20-22]). In
HCT116 cells, p21 expression parallels p53 activation;
however, data obtained in HT29 and HCT116-E6 cells
clearly indicate the existence of p53-independent path-
ways for p21 induction, that have been extensively charac-
terized (for a review see [23]) and can be activated to
variable extents (HCT116 E6 > HT29) upon exposure to
DOX. Interestingly, the extent of the cytotoxic effects
observed in the small panel of colon cell lines tested
rather seems to parallel the cells' ability to upregulate p21
(HCT116 > HCT116-E6 > HT29 > HCT116 p21-/-). This
result is somewhat unexpected: in fact, whereas the func-
tion of p21 in cell growth arrest following DNA damage
has been established for a long time [24], the role played
by this protein in the ultimate fate of tumor cells exposed
to cytotoxic agents is far from clear-cut [14,25]. In a
number of studies, p21 has actually been reported to pro-
tect tumor cells against cell death induced by enforced
p53 expression [26] or by low doses of cytotoxic agents
[13,27-30]. However, in other experimental settings, p53-
dependent or -independent induction of p21 expression
seems to be a prerequisite for apoptosis [31-34] and to
sensitize tumor cells to the action of different agents [35-
37]. The putative mechanisms by which p21 might actu-
Table 3: IC50values obtained after 24 h exposure to TPL followed by 1 h exposure to DOX and 72 h incubation in drug free medium 
(mean ± s.e.m. of 4–6 independent experiments).
DOX + TPL (IC25) + TPL (IC50) C.I.a
HCT116 0.38 ± 0.03 0.102 ± 0.04 0.053 ± 0.003 0.4–0.6
HT29 2.20 ± 0.11 1.06 ± 0.12 0.49 ± 0.015 0.6–0.8
HCT116 E6 0.77 ± 0.06 0.54 ± 0.6 0.24 ± 0.07 0.6–0.8
HCT116 p21-/- 5.457 ± 0.16 4.98 ± 0.15 2.549 ± 0.21 0.8–1.1
aCombination index (C.I.) ≈ 1.0: additivity; C.I.<1.0: synergy; C.I.>1.0: antagonism
Effect of 24 h pre-treatment with TPL on DOX IC50 values obtained in HCT116, HT29, HCT116 E6 and HCT116 p21-/- cells following 1 h exposure to DOX and 72 h in drug-fr emed umFigur  6
Effect of 24 h pre-treatment with TPL on DOX IC50 values 
obtained in HCT116, HT29, HCT116 E6 and HCT116 p21-/- 
cells following 1 h exposure to DOX and 72 h in drug-free 
medium. For each cell line, two TPL concentrations corre-
sponding to IC25 and IC50 (see table 2), were used. Mean ± 
s.e.m. of 4–6 experiments.Page 8 of 10
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but still await full elucidation.
Interestingly, the situation outlined by our results does
not seem to conform to either view: in fact, while induc-
tion of p21 in p53-proficient and -deficient cell lines is
associated with increased response to drug treatment, this
was not accompanied by a parallel increase in apoptotic
cells, as no significant differences in apoptosis were
observed between HCT116 cells and the 14-fold resistant
HCT-116 p21-/- cell line (figure 4). This suggests that
modes of cell death other than apoptosis may operate in
tumor cells following exposure to DOX, or, more gener-
ally, to DNA-damaging agents, a concept that is beginning
to be proposed by a number of Authors [39,40]; of note,
recent experimental evidence indicates p21 as one of the
major determinants of terminal growth arrest induced by
cytotoxic agents [41-43]. Therefore, although issues
related to terminal growth arrest and senescence have not
been specifically addressed in the present study, the possi-
bility that these phenomena might play a role linking cell
death to the observed increases in p21 levels should not
be disregarded.
The hypothesis that the cytotoxic response of the tumor
cell lines tested in the present study may depend on p21
induction is further corroborated by data obtained
following pre-treatment with the piperidine nitroxide
TPL. The choice of this compound was dictated by
previous findings indicating that TPL induces cell death in
a number of tumor cell lines irrespective of their p53 sta-
tus [15], and that it increases p21 levels in p53-null cells
[16]. The results of the present study show that TPL affects
the four colon cell lines to similar extents, thus confirming
that its growth inhibitory effect is independent of p53
function. HCT-116 p21-/- cells are actually slightly less
responsive than the other cell lines [even though the dif-
ference does not attain statistical significance), which sug-
gests the possibility that the effects of TPL are due in part
to its ability to increase p21 levels. Interestingly, the
nitroxide also induces p21 expression even in p53-defi-
cient cell lines; this observation suggests that TPL can acti-
vate p53-independent pathways for p21 induction, as
already noted following exposure of HT29 and HCT116
E6 cells to DOX. Moreover, activation of such pathways by
TPL appears to sensitize tumor cells to the action of DOX:
in fact, synergistic potentiation of DOX cytotoxicity is
achieved by TPL in those cell lines where p21 expression
can be induced, but only additive effects between TPL and
DOX are observed in HCT116 p21-/-, where p21 expres-
sion is constitutively absent.
Conclusions
In summary, the results of the present study strongly sug-
gest that 1) p21 induction may significantly contribute to
the response of colon adenocarcinoma cells to DOX treat-
ment; and 2) small molecules that can exploit p53-inde-
pendent pathways for p21 induction, such as TPL, may
find a place in chemotherapeutic protocols for the clinical
management of colorectal cancer, where p53 function is
often lost, due to genetic or epigenetic defects or to post-
transcriptional inactivating mechanisms.
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